Effect of Itraconazole on the Pharmacokinetics of Bardoxolone Methyl in Healthy Adults

Inclusion Criteria: * Male or female and age is between 18 and 55 years, inclusive; * Female subjects of childbearing potential must not be planning a pregnancy, pregnant, or lactating, and must have a negative serum pregnancy test result before enrollment into the study, and must be willing to use contraception as specified or abstain from sexual activity for the duration of the study; * If male, subject must be surgically sterile or practicing an approved method of contraception, from initial study drug administration through 90 days after administration of the last dose of study drug; * If male, subject agrees to abstain from sperm donation through 90 days after administration of the last dose of study drug; * Body Mass Index (BMI) is ≥ 18 to ≤31 kg/m2, inclusive; * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG), as judged by the investigator; * Must voluntarily sign and date each informed consent, approved by an Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures. Exclusion Criteria: * History of clinically significant drug allergies, including allergies to any of the components of the investigational product and/or clinically significant food allergies as determined by the investigator; * Presence or history of any significant cardiovascular, gastrointestinal, hepatic, renal, pulmonary, hematologic, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease, as determined by the investigator; * Presence of any other condition (including surgery) known to interfere with the absorption, distribution, metabolism, or excretion of medicines; * Known hypersensitivity to any component in the formulations of bardoxolone methyl, or SPORANOX®; * Requirement for any over-the-counter and/or prescription medication, vitamins, and/or herbal supplements on a regular basis; * Use of any medications (over-the-counter and/or prescription medication), vitamins, and/or herbal supplements, within the 30-day period prior to study drug administration or within 5 half-lives (if known), whichever is longer; * Recent (6-month) history of drug or alcohol abuse; * B-type natriuretic peptide (BNP) level \>200 pg/mL at screening; * Positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or HIV antibodies (HIV Ab) at screening; * Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to study drug administration; * Receipt of any investigational product within a time period equal to 10 half-lives of the product, if known, or a minimum of 30 days prior to study drug administration; * Positive screen results for drugs of abuse, alcohol, or cotinine at screening or Day -1; * Consumption of alcohol within 72 hours prior to study drug administration; * Consumption of grapefruit, grapefruit products, star fruit, star fruit products, or Seville oranges within the 72-hour period prior to study drug administration; * Use of tobacco or nicotine-containing products within the 6-month period preceding study drug administration; * Current enrollment in another clinical study; * Screening laboratory analyses that show any of the following abnormal laboratory results: 1. Alanine transaminase (ALT) or aspartate aminotransferase (AST) levels above the upper limit of normal (ULN); 2. Clinically significant abnormal ECG; ECG with QTc using Fridericia's correction formula (QTcF) \> 450 msec is exclusionary; 3. Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive either bardoxolone methyl or itraconazole.